Atrasentan in Patients with IgA Nephropathy

202478 citationsJournal Articlegreen Open Access

Authors

Hiddo J.L. Heerspink · University of Groningen

Meg Jardine · National Health and Medical Research Council

Donald E. Kohan · University of Utah Health Care

Richard Lafayette · Stanford University

Adeera Levin · University of British Columbia

Adrian Liew · Mount Elizabeth Novena Hospital

Hong Zhang

Abstract

In this prespecified interim analysis, atrasentan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo in patients with IgA nephropathy. (Funded by Novartis; ALIGN ClinicalTrials.gov number, NCT04573478.).

Topics & Keywords

Renal Diseases and Glomerulopathies Systemic Sclerosis and Related Diseases Chronic Kidney Disease and Diabetes

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 392, Issue 6, pp. 544-554

DOI: 10.1056/nejmoa2409415

Field-Weighted Citation Impact: 26.12